US2020129461A1PendingUtilityA1
Compositions Comprising Cancer Drug-Fatty Acid Conjugates
Est. expiryOct 29, 2030(~4.3 yrs left)· nominal 20-yr term from priority
A61K 31/121A61K 47/44A61K 31/202A61K 31/201A61K 9/2013A61K 31/12A61K 31/196A61K 31/704A61K 47/10A61K 31/25A61K 31/616A61K 31/337A61K 47/14A61K 9/08A61K 31/60A61K 47/22Y02A50/411A61K 31/192Y02A50/30
82
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Claims
exact text as granted — not AI-modified1 . A composition comprising a lipid-adjuvant attached to a plant alkaloid cancer drug, wherein the lipid-adjuvant is a fatty acid comprising 12 and 24 carbon atoms and a functional group.
2 . The composition according to claim 1 , wherein the attachment is by an ester linkage.
3 . The composition according to claim 1 , wherein the functional group comprises an oxygen.
4 . The composition according to claim 1 , wherein the lipid-adjuvant is attached to a carboxylic acid or hydroxyl functional group present of the plant alkaloid cancer drug.
5 . The composition according to claim 1 , wherein the fatty acid is a saturated fatty acid or an unsaturated fatty acid.
6 . The composition according to claim 1 , wherein the fatty acid is an omega fatty acid.
7 . The composition according to claim 1 , wherein the fatty acid has between 12 and 24 carbon atoms.
8 . The composition according to claim 1 , wherein the fatty acid is a palmitic acid, a palmitoleic acid, a sapienic acid, a margaric acid, a stearic acid, an oleic acid, an elaidic acid, a vaccenic acid, a linoleic acid, a linoelaidic acid, an α-linolenic acid, a γ-linolenic acid, a stearidonic acid, a nonadecylic acid, an arachidic acid, an eicosenoic acid, a dihomo-γ-linolenic acid, a mead acid, an arachidonic acid, or an eicosapentaenoic acid.
9 . The composition according to claim 1 , wherein the plant alkaloid cancer drug includes a vinca alkaloid, a podophyllotoxin, or a taxane.
10 . The composition according to claim 9 , wherein the vinca alkaloid includes Vincristine, Vinblastine, Vinorelbine, or Vindesine.
11 . The composition according to claim 9 , wherein the podophyllotoxin includes Etoposide or Teniposide.
12 . The composition according to claim 9 , wherein the taxane includes Docetaxel or Ortataxel.
13 . A composition comprising a lipid-adjuvant attached to a taxane by an ester linkage, wherein the lipid-adjuvant is a fatty acid comprising 12 and 24 carbon atoms and a functional group.
14 . The composition according to claim 13 , wherein the functional group comprises an oxygen.
15 . The composition according to claim 13 , wherein the lipid-adjuvant is attached to a carboxylic acid or hydroxyl functional group present of the plant alkaloid cancer drug.
16 . The composition according to claim 13 , wherein the fatty acid is a saturated fatty acid or an unsaturated fatty acid.
17 . The composition according to claim 16 , wherein the unsaturated fatty acid is a cis isomer or a trans isomer.
18 . The composition according to claim 13 , wherein the fatty acid is an omega fatty acid.
19 . The composition according to claim 13 , wherein the fatty acid is a palmitic acid, a palmitoleic acid, a sapienic acid, a margaric acid, a stearic acid, an oleic acid, an elaidic acid, a vaccenic acid, a linoleic acid, a linoelaidic acid, an α-linolenic acid, a γ-linolenic acid, a stearidonic acid, a nonadecylic acid, an arachidic acid, an eicosenoic acid, a dihomo-γ-linolenic acid, a mead acid, an arachidonic acid, or an eicosapentaenoic acid.
20 . The composition according to claim 9 , wherein the taxane includes Docetaxel or Ortataxel.Join the waitlist — get patent alerts
Track US2020129461A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.